The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Clinical Course of Oxaliplatin-Induced Neuropathy: Results From the Randomized Phase III Trial N08CB (Alliance)
Open accessAbstract
Purpose: Given that the clinical course of oxaliplatin-induced neuropathy is not well defined, the current study was performed to better understand clinical parameters associated with its presentation. Methods: Acute and chronic neuropathy was evaluated in patients receiving adjuvant FOLFOX (fluorouracil, leucovorin, and oxaliplatin) on study N08CB (North Central Cancer Treatment Group, Alliance). Acute neuropathy was assessed by having patients complete daily questionnaires for 6 days with each cycle of FOLFOX. Before each dose of FOLFOX and as long as 18 months after chemotherapy cessation, chronic neurotoxicity was assessed with use of the 20-item, European Organisation for Research and Treatment of Cancer quality-of-life questionnaire for patients with chemotherapy-induced peripheral neuropathy. Results: Three hundred eight (89%) of the 346 patients had at least one symptom of acute neuropathy with the first cycle of FOLFOX; these symptoms included sensitivity to touching cold items (71%), sensitivity to swallowing cold items (71%), throat discomfort (63%), or muscle cramps (42%). Acute symptoms peaked at day 3 and improved, although they did not always resolve completely between treatments. These symptoms were about twice as severe in cycles 2 through 12 as they were in cycle 1. For chronic neurotoxicity, tingling was the most severe symptom, followed by numbness and then pain. During chemotherapy, symptoms in the hands were more prominent than they were in the feet; by 18 months, symptoms were more severe in the feet than they were in the hands. Patients with more severe acute neuropathy during the first cycle of therapy experienced more chronic sensory neurotoxicity (P < .0001). Conclusion: Acute oxaliplatin-induced neuropathy symptoms do not always completely resolve between treatment cycles and are only half as severe on the first cycle as compared with subsequent cycles. There is a correlation between the severities of acute and chronic neuropathies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Chemotherapy-induced peripheral neuropathy
Quasthoff, S., & Hartung, H. P. (2002) · Journal of Neurology · doi:10.1007/pl00007853 · Cited by 966
de Boer, A. G. E. M., van Lanschot, J. J. B., Stalmeier, P. F. M., van Sandick, J. W., Hulscher, J. B. F., de Haes, J. C. J. M., & Sprangers, M. A. G. (2004) · Quality of Life Research · doi:10.1023/b:qure.0000018499.64574.1f · Cited by 743
Kindler, C. H., Harms, C., Amsler, F., Ihde-Scholl, T., & Scheidegger, D. (2000) · Anesthesia & Analgesia · doi:10.1097/00000539-200003000-00036 · Cited by 632
Postma, T. J., Aaronson, N. K., Heimans, J. J., Muller, M. J., Hildebrand, J. G., Delattre, J. Y., Hoang-Xuan, K., Lantéri-Minet, M., Grant, R., Huddart, R., et al. (2005) · European Journal of Cancer · doi:10.1016/j.ejca.2005.02.012 · Cited by 583
Mols, F., Beijers, T., Lemmens, V., van den Hurk, C. J., Vreugdenhil, G., & van de Poll-Franse, L. V. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.49.1514 · Cited by 359
Cisplatin induced Mitochondrial DNA damage in dorsal root ganglion neurons
Podratz, J. L., Knight, A. M., Ta, L. E., Staff, N. P., Gass, J. M., Genelin, K., Schlattau, A., Lathroum, L., & Windebank, A. J. (2011) · Neurobiology of Disease · doi:10.1016/j.nbd.2010.11.017 · Cited by 320
Self-citationNatural History of Paclitaxel-Associated Acute Pain Syndrome: Prospective Cohort Study NCCTG N08C1
Loprinzi, C. L., Reeves, B. N., Dakhil, S. R., Sloan, J. A., Wolf, S. L., Burger, K. N., Kamal, A., Le-Lindqwister, N. A., Soori, G. S., Jaslowski, A. J., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.33.0308 · Cited by 281
Self-citationLocke, D. E. C., Decker, P. A., Sloan, J. A., Brown, P. D., Malec, J. F., Clark, M. M., Rummans, T. A., Ballman, K. V., Schaefer, P. L., & Buckner, J. C. (2007) · Journal of Pain and Symptom Management · doi:10.1016/j.jpainsymman.2007.01.016 · Cited by 249
Land, S. R., Kopec, J. A., Cecchini, R. S., Ganz, P. A., Wieand, H. S., Colangelo, L. H., Murphy, K., Kuebler, J. P., Seay, T. E., Needles, B. M., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.6652 · Cited by 239
Argyriou, A. A., Cavaletti, G., Briani, C., Velasco, R., Bruna, J., Campagnolo, M., Alberti, P., Bergamo, F., Cortinovis, D., Cazzaniga, M., et al. (2013) · Cancer · doi:10.1002/cncr.27732 · Cited by 221
Tofthagen, C., Donovan, K. A., Morgan, M. A., Shibata, D., & Yeh, Y. (2013) · Supportive Care in Cancer · doi:10.1007/s00520-013-1905-5 · Cited by 190
Leonard, G. D., Wright, M. A., Quinn, M. G., Fioravanti, S., Harold, N., Schuler, B., Thomas, R. R., & Grem, J. L. (2005) · BMC Cancer · doi:10.1186/1471-2407-5-116 · Cited by 184
Acute Abnormalities of Sensory Nerve Function Associated With Oxaliplatin-Induced Neurotoxicity
Park, S. B., Goldstein, D., Lin, C. S.-Y., Krishnan, A. V., Friedlander, M. L., & Kiernan, M. C. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.3425 · Cited by 174
Ta, L. E., Low, P. A., & Windebank, A. J. (2009) · Molecular Pain · doi:10.1186/1744-8069-5-9 · Cited by 164
Self-citationReeves, B. N., Dakhil, S. R., Sloan, J. A., Wolf, S. L., Burger, K. N., Kamal, A., Le‐Lindqwister, N. A., Soori, G. S., Jaslowski, A. J., Kelaghan, J., et al. (2012) · Cancer · doi:10.1002/cncr.27489 · Cited by 161
Self-citationWolf, S. L., Barton, D. L., Qin, R., Wos, E. J., Sloan, J. A., Liu, H., Aaronson, N. K., Satele, D., Mattar, B. I., Green, N. B., et al. (2011) · Supportive Care in Cancer · doi:10.1007/s00520-011-1141-9 · Cited by 132
Self-citationCisplatin neuropathy: clinical course and neurophysiological findings
LoMonaco, M., Milone, M., Batocchi, A. P., Padua, L., Restuccia, D., & Tonali, P. A. (1992) · Journal of Neurology · doi:10.1007/bf00839140 · Cited by 109
Kidwell, K., Yothers, G., Ganz, P. A., Land, S. R., Ko, C. Y., Cecchini, R. S., Kopec, J. A., & Wolmark, N. (2012) · Cancer · doi:10.1002/cncr.27593 · Cited by 95
Predicting Acute and Persistent Neuropathy Associated With Oxaliplatin
Alejandro, L. M., Behrendt, C. E., Chen, K., Openshaw, H., & Shibata, S. (2012) · American Journal of Clinical Oncology · doi:10.1097/coc.0b013e318246b50d · Cited by 83
Progressive paresthesias after cessation of therapy with very high-dose cisplatin
Grunberg, S. M., Sonka, S., Stevenson, L. L., et al. (1989) · Cancer Chemotherapy and Pharmacology · doi:10.1007/bf00694340 · Cited by 82
Peripheral Neuropathy in Patients With Colorectal Cancer Receiving Oxaliplatin
Tofthagen, C., McAllister, R. D., & McMillan, S. C. (2011) · Clinical journal of oncology nursing · doi:10.1188/11.cjon.182-188 · Cited by 78
Visual analogue scales and assessment of quality of life in cancer.
Hauser, K., & Walsh, D. (2008) · PubMed · Cited by 40
Cited by
Loprinzi, C. L., Lacchetti, C., Bleeker, J., Cavaletti, G., Chauhan, C., Hertz, D. L., Kelley, M. R., Lavino, A., Lustberg, M. B., Paice, J. A., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.20.01399 · Cited by 1,113
Self-citationChemotherapy-induced peripheral neuropathy: a current review
Staff, N. P., Grisold, A., Grisold, W., & Windebank, A. J. (2017) · Annals of Neurology · doi:10.1002/ana.24951 · Cited by 908
Self-citationChemotherapy-Induced Peripheral Neuropathy: Epidemiology, Pathomechanisms and Treatment
Burgess, J., Ferdousi, M., Gosal, D., Boon, C., Matsumoto, K., Marshall, A., Mak, T., Marshall, A., Frank, B., Malik, R. A., et al. (2021) · Oncology and Therapy · doi:10.1007/s40487-021-00168-y · Cited by 306
Wang, M., Cheng, H. L., Lopez, V., Sundar, R., Yorke, J., & Molassiotis, A. (2019) · BMC Cancer · doi:10.1186/s12885-019-6352-3 · Cited by 42
Slater, S., Bryant, A., Chen, H.-C., Begum, R., Rana, I., Aresu, M., Peckitt, C., Zhitkov, O., Lazaro-Alcausi, R., Borja, V., et al. (2023) · BMC Cancer · doi:10.1186/s12885-023-10699-4 · Cited by 37
Metadata
- Authors
- Pachman, D. R., Qin, R., Seisler, D. K., Smith, E. M. L., Beutler, A. S., Ta, L. E., Lafky, J. M., Wagner-Johnston, N. D., Ruddy, K. J., Dakhil, S., Staff, N. P., Grothey, A., & Loprinzi, C. L.
- Venue
- Journal of Clinical Oncology
- Published
- 2015-10-20
- Volume
- 33
- Issue
- 30
- Pages
- 3416-3422
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2156409369
- Cited by
- 309
- References
- 22
- FWCI
- 7.67
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.